Aerocrine’s NIOX MINO and the test kits receive Australian marketing approval

Aerocrine AB (STO:AERO) announces that its airway inflammation monitor, NIOX MINO®, and the NIOX MINO® Test Kit, have received marketing approval for the Australian market. An approval is an important step towards receiving reimbursement for inflammation monitoring with FeNO in asthma management.

Australian Therapeutic Goods Administration (TGA), decided in early May 2012 to give NIOX MINO® Airway Inflammation Monitor and NIOX MINO® Test Kit marketing approval in Australia. NIOX MINO® and the Test Kits will be marketed and sold by Aerocrine's distributor Niche Medical (Innervate Pty Ltd). The approval has lead to that Aerocrine, in cooperation with its distributor, now develops the strategy for obtaining reimbursement from public as well as private health insurance programs on the Australian market. These components are key factors for the company's opportunities to grow sales in the future.

- All progress in Australia is important since there is a great potential in that market. But it is important to remember that we have quite a long way to go before sales can take off. From a strategic perspective, the Australian market is very important as Australia have a number of recognized and prominent research groups working with FeNO. The marketing approval enables us to reach out to these groups as well as opens up for strategic sales, which increases the acceptance and awareness of our products and the method, says Morten Gunvad, VP Commercial Operations Europe & Asia at Aerocrine.